| | | | |
| |  | | Exhibit 5.1 |
31 July 2018
Autolus Therapeutics plc
Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom
Re: | Autolus Therapeutics plc — Registration Statement onForm S-8 — Exhibit 5.1 |
Ladies and Gentlemen:
We have acted as English legal advisers to Autolus Therapeutics plc, a public limited company incorporated in England and Wales (the “Company”) in connection with the preparation and filing of the registration statement on FormS-8 to which this letter is attached as an exhibit (such registration statement, including the documents incorporated by reference therein, the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to the U.S. Securities Act of 1933, as amended (the “Securities Act”). For the purposes of this letter, the ordinary shares in the capital of the Company each having a nominal value of $0.000042 are referred to as “Ordinary Shares”.
As set out in the Registration Statement, it is proposed that up to 4,742,161 Ordinary Shares (the “Shares”). The Shares will be allotted and issued upon the exercise or settlement of equity awards granted under (i) the Autolus Limited 2017 Share Option Plan as adopted by the board of Autolus Limited (the “Autolus Limited Board”) on 22 February 2017 (“2017 Share Option Plan”), the Autolus Limited 2017 Share Option Plan — U.S.Sub-Plan for U.S. Participants (“2017 U.S. Employee Plan”) and the Autolus Limited 2017Non-Employee Share Option PlanSub-Plan for U.S. Participants (“2017 U.S.Non-Employee Plan”) (collectively, the 2017 Share Option Plan, the 2017 U.S. Employee Plan and the 2017 U.S.Non-Employee Plan are referred to as the “2017 Plan”) and (ii) the Autolus Therapeutics plc 2018 Equity Incentive Plan adopted by the Board on 15 June 2018 and approved by the Company’s shareholders on 15 June 2018 (the “2018 Incentive Plan”) which includes Ordinary Shares reserved for issuance under the Autolus Therapeutics plc 2018Non-Employee Sub Plan (the “Sub-Plan” and collectively with the 2018 Incentive Plan, the “2018 Plan”, and together with the 2017 Plan, the “Plans” and each, a “Plan”).
We understand that the existing issued Ordinary Shares are not, and are not intended to be, admitted to trading on any market or exchange, or otherwise listed, in the United Kingdom.
In connection with the preparation and filing of a registration statement onForm S-8, we have been asked to provide opinions on certain matters, as set out below. We have taken instruction in this regard solely from the Company.
Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS, UK
t: +44 (0) 20 7583 4055 f: +44 (0) 20 7785 9355 cooley.com
Cooley (UK) LLP is a limited liability partnership and is registered in England and Wales with registered number OC395270. Our registered office is at the address above. Cooley (UK) LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK) LLP and their professional qualifications is open to inspection at its registered office. The word ‘partner,’ used in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated firm) of equivalent standing.